Sector ratings Protalix BioTherapeutics, Inc.

Stocks

Market Closed - NYSE 16:00:00 2026-09-30 EDT			5-day change	1st Jan Change
2.760 ^USD	+2.60%		-1.43%	+53.33%

09-16	Protalix BioTherapeutics, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-16-2026 01:05 PM
08-12	Protalix BioTherapeutics, Inc., Q2 2026 Earnings Call, Aug 12, 2026

Sector:

Location:

X axis:

Main competitors

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Capi.($)	Investor	ESG MSCI	Fundamentals	Global Valuation
PROTALIX BIOTHERAPEUTICS, INC.	217M	-	-	-	-
ELI LILLY AND COMPANY	1,056B		A
JOHNSON & JOHNSON	645B		BBB
ABBVIE INC.	465B		AAA		-
MERCK & CO., INC.	368B		A
ROCHE HOLDING AG	335B		AA
NOVARTIS AG	275B		AAA
ASTRAZENECA PLC	255B		A
AMGEN INC.	229B		A
GILEAD SCIENCES, INC.	188B		AA
NOVO NORDISK A/S	169B		BBB
PFIZER INC.	164B		A
VERTEX PHARMACEUTICALS INCORPORATED	134B		AA
BRISTOL-MYERS SQUIBB COMPANY	128B		A
MCKESSON CORPORATION	101B	-	AA	-	-
GSK PLC	98.21B		AA
SANOFI	97.03B		A
MODERNA, INC.	81.23B	-	BBB	-	-
REGENERON PHARMACEUTICALS, INC.	74.94B		BBB
MERCK KGAA	67.69B		AAA
Average	246.51B		AA
Weighted average by Cap.			AA